Skip to main content

Advertisement

SpringerLink
Log in

Multicentric Castleman’s Disease: A Challenging Diagnosis

  • Review
  • Published:
Pathology & Oncology Research

Abstract

Multicentric Castleman’s disease (MCD) is a sytemic disorder with flares of non-specific symptoms suggestive of a chronic inflammatory syndrome. It is typically accompanied by generalized lymphadenopathy and multiorgan involvement. Histologically, two main variants of Castleman’s disease exist, the hyalin vascular type and the plasma cell variant. Upon localization unicentric (localized), and multicentric (diffuse, systemic) subtypes can be distinguished with more different disease outcomes. Patients often exhibit acute phase reactions and several autoimmune phenomena, and are at high risk for developing malignancies. Both the idiopathic and the HHV-8-driven infectious forms of MCD represent distinct disease entities with a less favorable prognosis. The induction of human IL-6 excess via yet unknown upstream mechanisms, and overexpression of viral IL-6 by HHV-8 can pivotally influence MCD biology. Based on the role of IL-6 in pathogenesis, MCD is also designated as IL-6 lymphadenopathy. To date there are no direct therapeutic evidences, but having been translated to daily practice the main regulatory factors may serve as promising therapeutic targets.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Castleman B, Towne VW (1954) Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med 251:396–400

    Article  PubMed  CAS  Google Scholar 

  2. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W (1998) The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 128:657–662

    Article  PubMed  CAS  Google Scholar 

  3. Roca B (2009) Castleman’s disease. A review. AIDS Rev 11:3–7.

    PubMed  Google Scholar 

  4. Keller AR, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670–683

    Article  PubMed  CAS  Google Scholar 

  5. Gaba AR, Stein RS, Sweet DL, Variakojis D (1978) Multicentric giant lymph node hyperplasia. Am J Clin Pathol 69:86–90

    PubMed  CAS  Google Scholar 

  6. Peterson BA, Frizzera G (1993) Multicentric Castleman’s disease. Semin Oncol 20:636–647

    PubMed  CAS  Google Scholar 

  7. Maslovsky I, Uriev L, Lugassy G (2000) The heterogeneity of Castleman disease: report of five cases and review of the literature. Am J Med Sci 320:292–295

    Article  PubMed  CAS  Google Scholar 

  8. Waterston A, Bower M (2004) Fifty years of multicentric Castleman’s disease. Acta Oncol 43:698–704

    Article  PubMed  Google Scholar 

  9. Frizzera G, Peterson BA, Bayrd ED, Goldman A (1985) A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 3:1202–1216

    PubMed  CAS  Google Scholar 

  10. Frizzera G (2001) Atypical lymphoproliferative disorders. In: Knowles DM (ed) Neoplastic hematopathology. Lippincott, Williams and Wilkins, Philadelphia, pp 595–621

    Google Scholar 

  11. Collins LS, Fowler A, Tong CY, de Ruiter A (2006) Multicentric Castleman’s disease in HIV infection. Int J STD AIDS 17:19–24

    Article  PubMed  CAS  Google Scholar 

  12. Soulier J, Grollet L, Oksenhendler E et al (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 86:1276–1280

    PubMed  CAS  Google Scholar 

  13. Cronin DM, Warnke RA (2009) Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 16:236–246

    Article  PubMed  Google Scholar 

  14. Shahidi H, Myers JL, Kvale PA (1995) Castleman’s disease. Mayo Clin Proc 70:969–977

    Article  PubMed  CAS  Google Scholar 

  15. Seida A, Wada J, Morita Y et al (2004) Multicentric Castleman’s disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury? Am J Kidney Dis 43:E3–E9

    Article  PubMed  Google Scholar 

  16. Suneja S, Chidambaram M, Herzenberg AM, Bargman JM (2009) Kidney involvement in multicentric castleman disease. Am J Kidney Dis 53:550–554

    Article  PubMed  Google Scholar 

  17. Guihot A, Couderc LJ, Agbalika F et al (2005) Pulmonary manifestations of multicentric Castleman’s disease in HIV infection: a clinical, biological and radiological study. Eur Respir J 26:118–125

    Article  PubMed  CAS  Google Scholar 

  18. Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H (1985) Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 16:162–172

    Article  PubMed  CAS  Google Scholar 

  19. Gessain A, Sudaka A, Brière J et al (1996) Kaposi sarcoma-associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman’s disease: is there any relevant association in non-human immunodeficiency virus-infected patients? Blood 87:414–416

    PubMed  CAS  Google Scholar 

  20. Izuchukwu IS, Tourbaf K, Mahoney MC (2003) An unusual presentation of Castleman’s disease: a case report. BMC Infect Dis 3:20

    Article  PubMed  Google Scholar 

  21. Oksenhendler E, Duarte M, Soulier J et al (1996) Multicentric Castleman’s disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 10:61–67

    Article  PubMed  CAS  Google Scholar 

  22. Oksenhendler E, Boulanger E, Galicier L et al (2002) High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 99:2331–2336

    Article  PubMed  CAS  Google Scholar 

  23. Larroche C, Cacoub P, Soulier J et al (2002) Castleman’s disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol 69:119–126

    Article  PubMed  Google Scholar 

  24. Du MQ, Liu H, Diss TC et al (2001) Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97:2130–2136

    Article  PubMed  CAS  Google Scholar 

  25. Dupin N, Diss TL, Kellam P et al (2000) HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95:1406–1412

    PubMed  CAS  Google Scholar 

  26. Kojima M, Nakamura S, Nishikawa M, Itoh H, Miyawaki S, Masawa N (2005) Idiopathic multicentric Castleman’s disease. A clinicopathologic and immunohistochemical study of five cases. Pathol Res Pract 201:325–332

    Article  PubMed  Google Scholar 

  27. Kojima M, Nakamura S, Itoh H et al (1997) Systemic lupus erythematosus (SLE) lymphadenopathy presenting with histopathologic features of Castleman’ disease: a clinicopathologic study of five cases. Pathol Res Pract 193:565–571

    Article  PubMed  CAS  Google Scholar 

  28. Ioachim HL, Cronin W, Roy M, Maya M (1990) Persistent lymphadenopathies in people at high risk for HIV infection. Clinicopathologic correlations and long-term follow-up in 79 cases. Am J Clin Pathol 93:208–218

    PubMed  CAS  Google Scholar 

  29. Kojima M, Nakamura S, Shimizu K et al (2004) Clinical implication of idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobulinemia: a report of 16 cases. Int J Surg Pathol 12:25–30

    Article  PubMed  Google Scholar 

  30. Frizzera G, Banks PM, Massarelli G, Rosai J (1983) A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease. Pathological findings in 15 patients. Am J Surg Pathol 7:211–231

    Article  PubMed  CAS  Google Scholar 

  31. Koo CH, Nathwani BN, Winberg CD, Hill LR, Rappaport H (1984) Atypical lymphoplasmacytic and immunoblastic proliferation in lymph nodes of patients with autoimmune disease (autoimmune-disease-associated lymphadenopathy). Med (Baltimore) 63:274–290

    CAS  Google Scholar 

  32. Bianchi MM, Narváez J, Santo P et al (2009) Multicentric Castleman’s disease mimicking adult-onset Still’s disease. Joint Bone Spine 76:304–307

    Article  PubMed  Google Scholar 

  33. Bonekamp D, Horton KM, Hruban RH, Fishman EK (2011) Castleman disease: the great mimic. Radiographics 31:1793–1807

    Article  PubMed  Google Scholar 

  34. Polizzotto MN, Uldrick TS, Hu D, Yarchoan R (2012) Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. Front Microbiol 3:73

    Article  PubMed  CAS  Google Scholar 

  35. Nishimoto N, Kishimoto T (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2:619–626

    Article  PubMed  CAS  Google Scholar 

  36. Kishimoto T (2006) Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 8:S2

    Article  PubMed  Google Scholar 

  37. Kishimoto T (1989) The biology of interleukin-6. Blood 74:1–10

    PubMed  CAS  Google Scholar 

  38. Vinzio S, Ciarloni L, Schlienger JL, Rohr S, Méchine A, Goichot B (2008) Isolated microcytic anemia disclosing a unicentric Castleman disease: the interleukin-6/hepcidin pathway? Eur J Intern Med 19:367–369

    Article  PubMed  CAS  Google Scholar 

  39. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101:2461–2463

    Article  PubMed  CAS  Google Scholar 

  40. Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ (2008) HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis 47:1209–1215

    Article  PubMed  Google Scholar 

  41. Moore PS, Chang Y (1995) Detection of herpesvirus-like DNA sequences in Kaposi’s sarcoma in patients with and without HIV infection. N Engl J Med 332:1181–1185

    Article  PubMed  CAS  Google Scholar 

  42. Davis DA, Humphrey RW, Newcomb FM et al (1997) Detection of serum antibodies to a Kaposi’s sarcoma-associated herpesvirus-specific peptide. J Infect Dis 175:1071–1079

    Article  PubMed  CAS  Google Scholar 

  43. Kedes DH, Ganem D, Ameli N, Bacchetti P, Greenblatt R (1997) The prevalence of serum antibody to human herpesvirus 8 (Kaposi sarcoma-associated herpesvirus) among HIV-seropositive and high-risk HIV-seronegative women. JAMA 277:478–481

    Article  PubMed  CAS  Google Scholar 

  44. Pauk J, Huang ML, Brodie SJ et al (2000) Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 343:1369–1377

    Article  PubMed  CAS  Google Scholar 

  45. Regamey N, Tamm M, Wernli M et al (1998) Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med 339:1358–1363

    Article  PubMed  CAS  Google Scholar 

  46. Levi JE, Nascimento MC, Sumita LM et al (2011) Non-detection of human herpesvirus 8 (HHV-8) DNA in HHV-8-seropositive blood donors from three Brazilian regions. PLoS One 6:e23546

    Article  PubMed  CAS  Google Scholar 

  47. Damania B (2007) DNA tumor viruses and human cancer. Trends Microbiol 15:38–44

    Article  PubMed  CAS  Google Scholar 

  48. Fukumoto H, Kanno T, Hasegawa H, Katano H (2011) Pathology of Kaposi’s Sarcoma-Associated Herpesvirus infection. Front Microbiol 2:175

    Article  PubMed  Google Scholar 

  49. Bélec L, Mohamed AS, Authier FJ et al (1999) Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman’s disease. Blood 93:3643–3653

    PubMed  Google Scholar 

  50. Yamasaki S, Iino T, Nakamura M et al (2003) Detection of human herpesvirus-8 in peripheral blood mononuclear cells from adult Japanese patients with multicentric Castleman’s disease. Br J Haematol 120:471–477

    Article  PubMed  Google Scholar 

  51. Darazam IA, Mansouri SD, Karimi S et al (2010) A 25-year-old woman with cough, constitutional symptoms and lymphadenopathy. Tanaffos 9:80–83

    Google Scholar 

  52. Schulte KM, Talat N (2010) Castleman’s disease–a two compartment model of HHV8 infection. Nat Rev Clin Oncol 7:533–543

    Article  PubMed  CAS  Google Scholar 

  53. Martró E, Cannon MJ, Dollard SC et al (2004) Evidence for both lytic replication and tightly regulated human herpesvirus 8 latency in circulating mononuclear cells, with virus loads frequently below common thresholds of detection. J Virol 78:11707–11714

    Article  PubMed  Google Scholar 

  54. Neipel F, Albrecht JC, Ensser A et al (1997) Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol 71:839–842

    PubMed  CAS  Google Scholar 

  55. Cesarman E (2011) Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett 305:163–174

    Article  PubMed  CAS  Google Scholar 

  56. El-Daly H, Bower M, Naresh KN (2010) Follicular dendritic cells in multicentric Castleman disease present human herpes virus type 8 (HHV8)-latent nuclear antigen 1 (LANA1) in a proportion of cases and is associated with an enhanced T-cell response. Eur J Haematol 84:133–136

    Article  PubMed  Google Scholar 

  57. El-Osta HE, Kurzrock R (2011) Castleman’s disease: from basic mechanisms to molecular therapeutics. Oncologist 16:497–511

    Article  PubMed  CAS  Google Scholar 

  58. Casper C (2005) The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 129:3–17

    Article  PubMed  Google Scholar 

  59. Dispenzieri A, Gertz MA (2005) Treatment of Castleman’s disease. Curr Treat Options Oncol 6:255–266

    Article  PubMed  Google Scholar 

  60. Gill PS, Loureiro C, Bernstein-Singer M, Rarick MU, Sattler F, Levine AM (1989) Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 110:937–940

    Article  PubMed  CAS  Google Scholar 

  61. Lajoie G, Kumar S, Min KW, Silva FG (1995) Renal thrombotic microangiopathy associated with multicentric Castleman’s disease. Report of two cases. Am J Surg Pathol 19:1021–1028

    Article  PubMed  CAS  Google Scholar 

  62. Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A (2008) Multicentric Castleman’s disease in HIV infection: a systematic review of the literature. AIDS Rev 10:25–35

    PubMed  Google Scholar 

  63. Seo HY, Kim EB, Kim JW, Shin BK, Kim SJ, Kim BS (2009) Complete remission in a patient with human herpes virus-8 negative multicentric Castleman disease using CHOP chemotherapy. Cancer Res Treat 41:104–107

    Article  PubMed  Google Scholar 

  64. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B (1999) Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi’s sarcoma. AIDS 13:2105–2111

    Article  PubMed  CAS  Google Scholar 

  65. Zietz C, Bogner JR, Goebel FD, Löhrs U (1999) An unusual cluster of cases of Castleman’s disease during highly active antiretroviral therapy for AIDS. N Engl J Med 340:1923–1924

    Article  PubMed  CAS  Google Scholar 

  66. Berezne A, Agbalika F, Oksenhendler E (2004) Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood 103:4368–4369

    Article  PubMed  CAS  Google Scholar 

  67. Casper C, Nichols WG, Huang ML, Corey L, Wald A (2004) Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 103:1632–1634

    Article  PubMed  CAS  Google Scholar 

  68. Bower M, Powles T, Williams S et al (2007) Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 147:836–839

    Article  PubMed  Google Scholar 

  69. Gérard L, Bérezné A, Galicier L et al (2007) Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial. J Clin Oncol 25:3350–3356

    Article  PubMed  Google Scholar 

  70. Law AB, Ryan G, Lade S, Prince HM (2010) Development of Kaposi’s sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient. Int J Hematol 91:347–348

    Article  PubMed  Google Scholar 

  71. Nishimoto N, Sasai M, Shima Y et al (2000) Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95:56–61

    PubMed  CAS  Google Scholar 

  72. Nishimoto N, Kanakura Y, Aozasa K et al (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627–2632

    Article  PubMed  CAS  Google Scholar 

  73. Matsuyama M, Suzuki T, Tsuboi H et al (2007) Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease. Intern Med 46:771–774

    Article  PubMed  Google Scholar 

  74. Higuchi T, Nakanishi T, Takada K et al (2010) A case of multicentric Castleman’s disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab. J Korean Med Sci 25:1364–1367

    Article  PubMed  Google Scholar 

  75. Műzes G, Sipos F, Csomor J, Sréter L (2012) Successful tocilizumab treatment in a patient with HHV8-positive and HIV-negative multicentric Castleman’s disease of plasma cell type nonresponsive to R-CVP therapy. doi:10.1111/apm.12029

  76. van Rhee F, Fayad L, Voorhees P et al (2010) Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol 28:3701–3708

    Article  PubMed  Google Scholar 

  77. Starkey CR, Joste NE, Lee FC (2006) Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. Am J Hematol 81:303–304

    Article  PubMed  Google Scholar 

  78. Hess G, Wagner V, Kreft A, Heussel CP, Huber C (2006) Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Br J Haematol 134:544–545

    Article  PubMed  CAS  Google Scholar 

  79. Sobas MA, Alonso Vence N, Diaz Arias J, Bendaña Lopez A, Fraga Rodriguez M, Bello Lopez JL (2010) Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant). Ann Hematol 89:217–219

    Article  PubMed  Google Scholar 

  80. Galeotti C, Tran TA, Franchi-Abella S, Fabre M, Pariente D, Koné-Paut I (2008) IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report. J Pediatr Hematol Oncol 30:920–924

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2nd Department of Medicine, Semmelweis University, 1088, Budapest, Szentkirályi u. 46., Hungary

    Györgyi Műzes, Ferenc Sipos & Lídia Sréter

  2. 1st Department of Pathology and Experimental Oncology, Semmelweis University, 1088, Budapest, Üllői út 26., Hungary

    Judit Csomor

Authors
  1. Györgyi Műzes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ferenc Sipos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Judit Csomor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lídia Sréter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Györgyi Műzes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Műzes, G., Sipos, F., Csomor, J. et al. Multicentric Castleman’s Disease: A Challenging Diagnosis. Pathol. Oncol. Res. 19, 345–351 (2013). https://doi.org/10.1007/s12253-013-9619-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-013-9619-z

Keywords

Search

Navigation